Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targanta Therapeutics, a biopharmaceutical company, has appointed Stephane Bancel and Rosemary Crane to its board of directors, effective immediately.
Subscribe to our email newsletter
The newly appointed directors are expected to add deep operational and commercial expertise to the board as Targanta continues to build its infrastructure in support of the potential commercial launch of its lead antibiotic drug candidate, oritavancin.
Mr Bancel currently serves as CEO for bioMerieux, a company specialized in in vitro diagnostics. Mr Bancel holds a MS in biochemical engineering from the University of Minnesota and an MBA from Harvard Business School.
Most recently, Ms Crane was company group chairman of Johnson & Johnson’s $4.3 billion OTC and nutritionals business. Ms Crane is a graduate of the State University of New York where she received a BA in communications. Ms Crane also holds an MBA from Kent State University.
Mark Leuchtenberger, president and CEO of Targanta, said: “We are very pleased that Stephane and Rosemary have joined our board of directors. We believe that their contributions will be invaluable to Targanta as we continue to grow our organization and plan for the commercial launch of oritavancin.”